NCT00510497View on ClinicalTrials.gov

Autologous Dendritic Cell Vaccine in HIV1 Infection

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

July 31, 2007

Primary Completion Date

September 30, 2012

Study Completion Date

September 30, 2012

Conditions
HIV Infections
Interventions
BIOLOGICAL

Autologous HIV-1 ApB DC Vaccine

Autologous dendritic cells pulsed with autologous, inactivated HIV-1 infected, apoptotic cells given subcutaneously 3 times every other week plus a booster dose 2 weeks after start of treatment interruption

Trial Locations (1)

15213

University of Pittsburgh, Pittsburgh

All Listed Sponsors
collaborator

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

lead

Sharon Riddler

OTHER

NCT00510497 - Autologous Dendritic Cell Vaccine in HIV1 Infection | Biotech Hunter | Biotech Hunter